Bachem Reta refers to retatrutide peptide made by Swiss manufacturer Bachem. Learn what research shows, how it compares to alternatives, and safety basics.
"Bachem reta" refers to retatrutide, an investigational triple-receptor agonist peptide, in the context of Bachem, the Swiss peptide manufacturer. Bachem is a peptide producer and contract manufacturing partner, not the developer of the drug — retatrutide belongs to Eli Lilly and is not FDA-approved for any use. The phrase is best understood as a sourcing and research question rather than a treatment recommendation.
What "Bachem Reta" Actually Means
Bachem Holding AG, based in Bubendorf, Switzerland, is one of the world's largest independent peptide manufacturers. The company produces catalog peptides, custom synthesis projects, and GMP-grade active pharmaceutical ingredients for pharmaceutical and biotech clients.
Retatrutide — commonly shortened to "reta" — is a 39-amino-acid peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes under the development code LY3437943.
Combining the two names usually signals one of three things:
- A researcher trying to find out whether Bachem manufactures or distributes retatrutide.
- A buyer checking whether a vendor claiming to sell "Bachem reta" is legitimate.
- Someone comparing peptide manufacturers before ordering research material.
Bachem's official catalog and company announcements are the only reliable source for what Bachem actually sells. A third-party website that invokes the Bachem name is not proof of a Bachem product, and mislabeled listings are common in the research peptide market.
What Clinical Trials of Retatrutide Have Found
Retatrutide's most-cited human data come from a phase 2 trial published in the New England Journal of Medicine in 2023. In that study, 338 adults with obesity received weekly injections for 48 weeks, and average weight reduction reached roughly 24% at the highest dose tested.
Eli Lilly has since launched the phase 3 TRIUMPH program, with additional studies in type 2 diabetes and in knee osteoarthritis among people with obesity. Those results will determine whether retatrutide ever reaches the US market.
Retatrutide is not FDA-approved for human use in the United States, and it remains an investigational drug.
Trial participants received pharmaceutical-grade peptide, defined doses, and medical monitoring. Those conditions cannot be replicated with research-grade material purchased online.
How Retatrutide Compares With Other Incretin Peptides
| Compound | Receptor targets | Developer | US regulatory status |
|---|---|---|---|
| Semaglutide | GLP-1 | Novo Nordisk | FDA-approved (Ozempic, Wegovy) |
| Tirzepatide | GIP + GLP-1 | Eli Lilly | FDA-approved (Mounjaro, Zepbound) |
| Retatrutide | GLP-1 + GIP + glucagon | Eli Lilly | Investigational — not approved |
| Cagrilintide | Amylin | Novo Nordisk | Investigational — not approved |
| MOTS-c | Mitochondrial-derived peptide (metabolic signaling) | Research-stage | Not approved; no approved drug form |
When people search tirzepatide vs reta, the practical difference is approval status. Tirzepatide is available by prescription in the United States, and retatrutide is not.
Retatrutide has shown larger average weight reductions than tirzepatide in early data, but phase 2 studies are smaller and shorter than phase 3 studies. Direct head-to-head trials have not been completed.
Cagri Reta Blends and MOTS-c Stacks
Interest in cagri and reta comes from the idea of combining two appetite-suppressing mechanisms: amylin signaling from cagrilintide and triple incretin plus glucagon signaling from retatrutide. No published human trial has tested that combination.
Because of that gap, reported cagri reta blend benefits are anecdotal rather than measured. Any discussion of reta cagri blend side effects is extrapolated from the individual compounds, and overlapping nausea, vomiting, and delayed gastric emptying are plausible concerns.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied for its role in metabolic regulation, and human data on it are limited. Interest in mots-c and reta reflects a broader trend of stacking peptides with different proposed mechanisms, but the combination has not been evaluated in controlled research.
A straight reta vs mots-c comparison is really a comparison between an investigational incretin-class drug and an early-stage metabolic research peptide. They are not interchangeable, and neither is approved for human use.
Purity, Documentation, and Sourcing Checks
No regulatory agency oversees research peptides the way it oversees prescription drugs, so product quality varies widely. Anyone evaluating a supplier listing should verify several things before ordering.
- A third-party certificate of analysis (COA) with HPLC purity data and mass spectrometry confirmation.
- Lot numbers that match the vial label, the COA, and the vendor's records.
- Cold-chain shipping and storage documentation, since peptides degrade with heat exposure.
- Direct confirmation from the manufacturer that it actually produces the compound in question.
A generic COA template, a missing lot number, or a manufacturer name used without permission are all red flags. Price that sits far below the rest of the market is another warning sign.
Safety, Legality, and Practical Takeaways
Retatrutide is not FDA-approved, is not a controlled substance, and cannot be obtained with a US prescription. Products labeled "retatrutide" are typically sold as research chemicals marked "not for human use," which places the entire risk on the buyer.
Reported side effects in trials have been mostly gastrointestinal — nausea, diarrhea, vomiting, and constipation — along with injection-site reactions and increases in resting heart rate. Pancreatitis, gallbladder disease, and loss of lean body mass are also monitored across this drug class.
Anyone considering a GLP-1–related medication should talk with a licensed healthcare professional about approved options instead of using unapproved research peptides. Self-dosing with an investigational triple agonist carries unknown risks and no safety net.
Frequently Asked Questions
Is Bachem reta the same thing as retatrutide?
Yes. "Reta" is shorthand for retatrutide, and "bachem reta" is a phrase people use when connecting that compound to Bachem, a Swiss peptide manufacturer. Bachem is a peptide producer and contract manufacturing organization, while retatrutide itself is Eli Lilly's investigational drug. Confirming whether Bachem actually supplies the molecule requires checking with the company directly.
Is retatrutide FDA-approved in the United States?
No. Retatrutide remains an investigational drug and has not received FDA approval for weight loss, diabetes, or any other indication. Eli Lilly is running the phase 3 TRIUMPH program, and any approval decision would follow those results. Until then, no prescription version of retatrutide exists in the US.
What side effects have been reported with retatrutide?
In clinical trials, the most common side effects were gastrointestinal, including nausea, vomiting, diarrhea, and constipation. Researchers also monitored injection-site reactions, heart rate increases, gallbladder problems, and pancreatitis. Long-term safety data are still being collected, so anyone with concerns should consult a healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.